DaVita Inc. (DVA)
NYSE:DVA
DVA Stock Chart & Stats
$150.05
$0.74(0.48%)
At close: 4:00 PM EST
$150.05
$0.74(0.48%)
Day’s Range― - ―
52-Week Range$101.00 - $159.42
Previous CloseN/A
Volume85.32K
Average Volume (3M)824.99K
Market Cap
$10.02B
Enterprise Value$24.32B
Total Cash (Recent Filing)$782.05M
Total Debt (Recent Filing)$15.05B
Price to Earnings (P/E)10.4
Beta0.44
Next Earnings
Apr 30, 2026EPS Estimate
2.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.40
Shares Outstanding66,800,000
10 Day Avg. Volume663,862
30 Day Avg. Volume824,990
Financial Highlights & Ratios
PEG Ratio-1.11
Price to Book (P/B)-15.02
Price to Sales (P/S)0.72
P/FCF Ratio7.46
Enterprise Value/Market Cap2.43
Enterprise Value/Revenue1.78
Enterprise Value/Gross Profit5.77
Enterprise Value/Ebitda9.21
Forecast
1Y Price Target
$162.50Price Target Upside8.30% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)14.13
Revenue Forecast (FY)$13.96B
Bulls Say, Bears Say
Bulls Say
Home Health Services ProfitabilityAnalyst highlights that strategic investment in a profitable, scaled home health services business should contribute positively to earnings from the outset and strengthen consolidated results.
Missed-treatment ReductionAnalyst notes that targeted follow-up for patients who miss dialysis sessions can reduce missed treatments concentrated in a small group, preserving treatment volumes and preventing habit formation.
Outcomes-driven Volume GrowthManagement expects a return to sustainable non-acquired treatment volume growth by improving patient outcomes and reducing mortality, a historical driver of volume expansion.
Bears Say
Dialysis Technology Trial LimitationsAnalyst reports that new hemodiafiltration machines currently being trialed are not expected to meaningfully increase treatment volumes, limiting growth potential from the technology.
Health Policy HeadwindsHealth policy headwinds related to the ACA are expected to weigh on financial results and could pressure revenue and margins.
DaVita News
DVA FAQ
What was DaVita Inc.’s price range in the past 12 months?
DaVita Inc. lowest stock price was $101.00 and its highest was $159.42 in the past 12 months.
What is DaVita Inc.’s market cap?
DaVita Inc.’s market cap is $10.02B.
When is DaVita Inc.’s upcoming earnings report date?
DaVita Inc.’s upcoming earnings report date is Apr 30, 2026 which is in 17 days.
How were DaVita Inc.’s earnings last quarter?
DaVita Inc. released its earnings results on Feb 02, 2026. The company reported $3.4 earnings per share for the quarter, beating the consensus estimate of $3.242 by $0.158.
Is DaVita Inc. overvalued?
According to Wall Street analysts DaVita Inc.’s price is currently Undervalued.
Does DaVita Inc. pay dividends?
DaVita Inc. does not currently pay dividends.
What is DaVita Inc.’s EPS estimate?
DaVita Inc.’s EPS estimate is 2.33.
How many shares outstanding does DaVita Inc. have?
DaVita Inc. has 66,800,000 shares outstanding.
What happened to DaVita Inc.’s price movement after its last earnings report?
DaVita Inc. reported an EPS of $3.4 in its last earnings report, beating expectations of $3.242. Following the earnings report the stock price went up 21.171%.
Which hedge fund is a major shareholder of DaVita Inc.?
Currently, no hedge funds are holding shares in DVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
DaVita Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$162.50 (8.30% Upside)
$162.50 (8.30% Upside)
Blogger Sentiment
Bullish
DVA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 410.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 7.5%
Last 30 Days ▲ 7.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-2.15%
12-Months-Change
Fundamentals
Return on Equity
-160.63%
Trailing 12-Months
Asset Growth
0.76%
Trailing 12-Months
Company Description
DaVita Inc.
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services to 16,000 patients in risk-based integrated care arrangements and 7,000 patients in other integrated care arrangements; vascular access services; clinical research programs; physician services; and comprehensive kidney care services. As of December 31, 2021, it provided dialysis and administrative services in the United States through a network of 2,815 outpatient dialysis centers serving approximately 203,100 patients; and operated 339 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 39,900 patients. Further, the company provides acute inpatient dialysis services in approximately 850 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
DVA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balanced clear operational and financial progress—IKC clinical success and first profitable year, solid full-year adjusted OI and EPS, strong cash generation, disciplined capital returns, and constructive 2026 guidance—with persistent near-term challenges including treatment-volume pressure driven by elevated mortality, residual cyber-related losses, rising patient care costs (PCC +5.9% YoY), and payer headwinds from the expiration of enhanced premium tax credits (~$40M in 2026). Management emphasized actionable clinical initiatives and gave explicit multi-year targets, and the positive results and forward guidance slightly outweigh the headwinds.View all DVA earnings summariesDVA Revenue Breakdown
85.99% U.S. dialysis
14.01% Ancillary services
DVA Stock 12 Month Forecast
Average Price Target
$162.50
▲(8.30% Upside)
Technical Analysis
Fresenius Medical Care
―
HCA Healthcare
―
Encompass Health
―
Tenet Healthcare
―
The Ensign Group
―
Ownership Overview
Currently, No data available
---